{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:15:04Z","timestamp":1787886904756,"version":"build-2784847793"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council of Taiwan","doi-asserted-by":"crossref","award":["111-2113-M-038-004, 112-2113-M-038-001, 112-2320-B-038-004"],"award-info":[{"award-number":["111-2113-M-038-004, 112-2113-M-038-001, 112-2320-B-038-004"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan","award":["DP2-TMU-113-C-03"],"award-info":[{"award-number":["DP2-TMU-113-C-03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10495-024-02023-7","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T11:01:45Z","timestamp":1728730905000},"page":"2047-2073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"Bidyadhar","family":"Sethy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iin","family":"Narwanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zih-Yao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Bau","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ping","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,12]]},"reference":[{"key":"2023_CR1","doi-asserted-by":"crossref","unstructured":"Ferlay J, Colombet M, Soerjomataram I et al (2021) Cancer statistics for the year 2020: an overview. Int J Cancer","DOI":"10.1002\/ijc.33588"},{"key":"2023_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.21037\/atm.2020.03.194","volume":"8","author":"S Zhao","year":"2020","unstructured":"Zhao S, Zuo WJ, Shao ZM, Jiang YZ (2020) Molecular subtypes and precision treatment of triple-negative breast cancer. Ann Transl Med 8:499","journal-title":"Ann Transl Med"},{"key":"2023_CR3","doi-asserted-by":"crossref","unstructured":"Verza FA, Das U, Fachin AL, Dimmock JR, Marins M (2020) Roles of histone deacetylases and inhibitors in anticancer therapy. Cancers (Basel) 12","DOI":"10.3390\/cancers12061664"},{"key":"2023_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/14728222.2021.1860016","volume":"25","author":"S Kumar","year":"2021","unstructured":"Kumar S, Attrish D, Srivastava A et al (2021) Non-histone substrates of histone deacetylases as potential therapeutic targets in epilepsy. Expert Opin Ther Targets 25:75\u201385","journal-title":"Expert Opin Ther Targets"},{"key":"2023_CR5","doi-asserted-by":"publisher","first-page":"114582","DOI":"10.1016\/j.ejmech.2022.114582","volume":"240","author":"HY Chae","year":"2022","unstructured":"Chae HY, Park SY, Jha S et al (2022) Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay. Eur J Med Chem 240:114582","journal-title":"Eur J Med Chem"},{"key":"2023_CR6","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3390\/ph17050620","volume":"17","author":"A Curcio","year":"2024","unstructured":"Curcio A, Rocca R, Alcaro S, Artese A (2024) The histone deacetylase family: structural features and application of combined computational methods. Pharmaceuticals 17:620","journal-title":"Pharmaceuticals"},{"key":"2023_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/genes11050556","volume":"11","author":"G Milazzo","year":"2020","unstructured":"Milazzo G, Mercatelli D, Di Muzio G et al (2020) Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability. Genes 11:556","journal-title":"Genes"},{"key":"2023_CR8","doi-asserted-by":"publisher","first-page":"e1006349","DOI":"10.1371\/journal.pcbi.1006349","volume":"14","author":"M Narasumani","year":"2018","unstructured":"Narasumani M, Harrison PM (2018) Discerning evolutionary trends in post-translational modification and the effect of intrinsic disorder: analysis of methylation, acetylation and ubiquitination sites in human proteins. PLoS Comput Biol 14:e1006349","journal-title":"PLoS Comput Biol"},{"key":"2023_CR9","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.3390\/molecules26185606","volume":"26","author":"L M\u00e1rquez-Cantudo","year":"2021","unstructured":"M\u00e1rquez-Cantudo L, Ramos A, Coderch C, de Pascual-Teresa B (2021) Proteasomal degradation of Zn-dependent HDACs: the E3-ligases implicated and the designed protacs that enable degradation. Molecules 26:5606","journal-title":"Molecules"},{"key":"2023_CR10","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","volume":"13","author":"T Liang","year":"2023","unstructured":"Liang T, Wang F, Elhassan RM et al (2023) Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharm Sin B 13:2425\u20132463","journal-title":"Acta Pharm Sin B"},{"key":"2023_CR11","doi-asserted-by":"crossref","unstructured":"Raucci A, Castiello C, Mai A, Zwergel C, Valente S (2024) Heterocycles-containing HDAC inhibitors active in cancer: an overview of the last fifteen years. ChemMedChem n\/a:e202400194","DOI":"10.1002\/cmdc.202400194"},{"key":"2023_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2022.280996","volume":"108","author":"S Rai","year":"2023","unstructured":"Rai S, Kim WS, Ando K et al (2023) Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica 108:811\u2013821","journal-title":"Haematologica"},{"key":"2023_CR13","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-07-1461","volume":"14","author":"L Gore","year":"2008","unstructured":"Gore L, Rothenberg ML, O\u2019Bryant CL et al (2008) A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 14:4517\u20134525","journal-title":"Clin Cancer Res"},{"key":"2023_CR14","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","volume":"63","author":"TCS Ho","year":"2020","unstructured":"Ho TCS, Chan AHY, Ganesan A (2020) Thirty years of HDAC inhibitors: 2020 insight and hindsight. J Med Chem 63:12460\u201312484","journal-title":"J Med Chem"},{"key":"2023_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/med.21600","volume":"40","author":"D Tomaselli","year":"2020","unstructured":"Tomaselli D, Lucidi A, Rotili D, Mai A (2020) Epigenetic polypharmacology: a new frontier for epi-drug discovery. Med Res Rev 40:190\u2013244","journal-title":"Med Res Rev"},{"key":"2023_CR16","doi-asserted-by":"publisher","first-page":"112831","DOI":"10.1016\/j.ejmech.2020.112831","volume":"208","author":"X Peng","year":"2020","unstructured":"Peng X, Sun Z, Kuang P, Chen J (2020) Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. Eur J Med Chem 208:112831","journal-title":"Eur J Med Chem"},{"key":"2023_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12032-022-01731-x","volume":"39","author":"S Sofi","year":"2022","unstructured":"Sofi S, Mehraj U, Qayoom H et al (2022) Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications. Med Oncol 39:106","journal-title":"Med Oncol"},{"key":"2023_CR18","doi-asserted-by":"publisher","first-page":"1324001","DOI":"10.3389\/fphar.2024.1324001","volume":"15","author":"I Dakilah","year":"2024","unstructured":"Dakilah I, Harb A, Abu-Gharbieh E et al (2024) Potential of Cdc25 phosphatases in cancer research and treatment: key to precision medicine. Front Pharmacol 15:1324001","journal-title":"Front Pharmacol"},{"key":"2023_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrc2169","volume":"7","author":"R Boutros","year":"2007","unstructured":"Boutros R, Lobjois Ve DB (2007) Cdc25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 7:495\u2013507","journal-title":"Nat Rev Cancer"},{"key":"2023_CR20","doi-asserted-by":"publisher","first-page":"112374","DOI":"10.1016\/j.ejmech.2020.112374","volume":"201","author":"Y Tao","year":"2020","unstructured":"Tao Y, Hao X, Ding X et al (2020) Medicinal chemistry insights into novel Cdc25 inhibitors. Eur J Med Chem 201:112374","journal-title":"Eur J Med Chem"},{"key":"2023_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bcp.2014.01.022","volume":"88","author":"Y Yang","year":"2014","unstructured":"Yang Y, Yang WS, Yu T et al (2014) Novel anti-inflammatory function of NSC95397 by the suppression of multiple kinases. Biochem Pharmacol 88:201\u2013215","journal-title":"Biochem Pharmacol"},{"key":"2023_CR22","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1124\/mol.61.4.720","volume":"61","author":"JS Lazo","year":"2002","unstructured":"Lazo JS, Nemoto K, Pestell KE et al (2002) Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol 61:720\u2013728","journal-title":"Mol Pharmacol"},{"key":"2023_CR23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41598-019-38579-7","volume":"9","author":"Z Kabakci","year":"2019","unstructured":"Kabakci Z, K\u00e4ppeli S, Cant\u00f9 C et al (2019) Pharmacophore-guided discovery of Cdc25 inhibitors causing cell cycle arrest and tumor regression. Sci Rep 9:1335","journal-title":"Sci Rep"},{"key":"2023_CR24","first-page":"1317","volume":"60","author":"K Tamura","year":"2000","unstructured":"Tamura K, Southwick EC, Kerns J et al (2000) Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res 60:1317\u20131325","journal-title":"Cancer Res"},{"key":"2023_CR25","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1016\/j.bmc.2015.01.043","volume":"23","author":"KM George Rosenker","year":"2015","unstructured":"George Rosenker KM, Paquette WD, Johnston PA et al (2015) Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B. Bioorg Med Chem 23:2810\u20132818","journal-title":"Bioorg Med Chem"},{"key":"2023_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ejmech.2014.05.063","volume":"82","author":"Y Song","year":"2014","unstructured":"Song Y, Lin X, Kang D et al (2014) Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate. Eur J Med Chem 82:293\u2013307","journal-title":"Eur J Med Chem"},{"key":"2023_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mc.22094","volume":"54","author":"E Bana","year":"2015","unstructured":"Bana E, Sibille E, Valente S et al (2015) A novel coumarin-quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell death. Mol Carcinog 54:229\u2013241","journal-title":"Mol Carcinog"},{"key":"2023_CR28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ejmech.2017.04.012","volume":"134","author":"C Zwergel","year":"2017","unstructured":"Zwergel C, Czepukojc B, Evain-Bana E et al (2017) Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells. Eur J Med Chem 134:316\u2013333","journal-title":"Eur J Med Chem"},{"key":"2023_CR29","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1021\/jm0102046","volume":"44","author":"JS Lazo","year":"2001","unstructured":"Lazo JS, Aslan DC, Southwick EC et al (2001) Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem 44:4042\u20134049","journal-title":"J Med Chem"},{"key":"2023_CR30","doi-asserted-by":"publisher","first-page":"111696","DOI":"10.1016\/j.ejmech.2019.111696","volume":"183","author":"L Jing","year":"2019","unstructured":"Jing L, Wu G, Hao X et al (2019) Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries. Eur J Med Chem 183:111696","journal-title":"Eur J Med Chem"},{"key":"2023_CR31","doi-asserted-by":"publisher","first-page":"115505","DOI":"10.1016\/j.ejmech.2023.115505","volume":"258","author":"I Narwanti","year":"2023","unstructured":"Narwanti I, Yu ZY, Sethy B et al (2023) 6-Regioisomeric 5,8-quinolinediones as potent Cdc25 inhibitors against colorectal cancers. Eur J Med Chem 258:115505","journal-title":"Eur J Med Chem"},{"key":"2023_CR32","doi-asserted-by":"crossref","unstructured":"Mokhtari RB, Homayouni TS, Baluch N et al (2017) Combination therapy in combating cancer. Oncotarget 8","DOI":"10.18632\/oncotarget.16723"},{"key":"2023_CR33","doi-asserted-by":"publisher","first-page":"8977","DOI":"10.1021\/acs.jmedchem.0c00491","volume":"63","author":"T Liu","year":"2020","unstructured":"Liu T, Wan Y, Xiao Y, Xia C, Duan G (2020) Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy. J Med Chem 63:8977\u20139002","journal-title":"J Med Chem"},{"key":"2023_CR34","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.2174\/1568026619666181224095449","volume":"18","author":"L Zhao","year":"2018","unstructured":"Zhao L, Duan YT, Lu P et al (2018) Epigenetic targets and their inhibitors in cancer therapy. Curr Top Med Chem 18:2395\u20132419","journal-title":"Curr Top Med Chem"},{"key":"2023_CR35","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.bmcl.2019.06.059","volume":"29","author":"Y Yu","year":"2019","unstructured":"Yu Y, Ran D, Jiang J et al (2019) Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2. Bioorg Med Chem Lett 29:2136\u20132140","journal-title":"Bioorg Med Chem Lett"},{"key":"2023_CR36","doi-asserted-by":"publisher","first-page":"113588","DOI":"10.1016\/j.ejmech.2021.113588","volume":"222","author":"YC Duan","year":"2021","unstructured":"Duan YC, Zhang SJ, Shi XJ et al (2021) Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy. Eur J Med Chem 222:113588","journal-title":"Eur J Med Chem"},{"key":"2023_CR37","doi-asserted-by":"publisher","first-page":"115140","DOI":"10.1016\/j.ejmech.2023.115140","volume":"249","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wei Y, Wang X et al (2023) Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cells. Eur J Med Chem 249:115140","journal-title":"Eur J Med Chem"},{"key":"2023_CR38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bbrc.2023.04.116","volume":"665","author":"A Boos","year":"2023","unstructured":"Boos A, Gahr BM, Park DD et al (2023) HDAC1-deficiency affects the cell cycle axis Cdc25-Cdk1 causing impaired G2\/M phase progression and reduced cardiomyocyte proliferation in zebrafish. Biochem Biophys Res Commun 665:98\u2013106","journal-title":"Biochem Biophys Res Commun"},{"key":"2023_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12935-020-01304-w","volume":"20","author":"K Liu","year":"2020","unstructured":"Liu K, Zheng M, Lu R et al (2020) The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review. Cancer Cell Int 20:213","journal-title":"Cancer Cell Int"},{"key":"2023_CR40","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1083\/jcb.200903033","volume":"187","author":"A Cerqueira","year":"2009","unstructured":"Cerqueira A, Santamar\u00eda D, Mart\u00ednez-Pastor B, Cuadrado M, Fern\u00e1ndez-Capetillo O, Barbacid M (2009) Overall cdk activity modulates the DNA damage response in mammalian cells. J Cell Biol 187:773\u2013780","journal-title":"J Cell Biol"},{"key":"2023_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.canlet.2008.06.005","volume":"274","author":"G Eot-Houllier","year":"2009","unstructured":"Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C (2009) Histone deacetylase inhibitors and genomic instability. Cancer Lett 274:169\u2013176","journal-title":"Cancer Lett"},{"key":"2023_CR42","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0960-9822(99)80308-X","volume":"9","author":"A Hagting","year":"1999","unstructured":"Hagting A, Jackman M, Simpson K, Pines J (1999) Translocation of cyclin B1 to the nucleus at prophase requires a phosphorylation-dependent nuclear import signal. Curr Biol 9:680\u2013689","journal-title":"Curr Biol"},{"key":"2023_CR43","doi-asserted-by":"publisher","first-page":"8282","DOI":"10.1038\/sj.onc.1206011","volume":"21","author":"J Yuan","year":"2002","unstructured":"Yuan J, Eckerdt F, Bereiter-Hahn J, Kurunci-Csacsko E, Kaufmann M, Strebhardt K (2002) Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene 21:8282\u20138292","journal-title":"Oncogene"},{"key":"2023_CR44","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1021\/acs.jmedchem.0c01967","volume":"64","author":"JYW Mak","year":"2021","unstructured":"Mak JYW, Wu KC, Gupta PK et al (2021) HDAC7 inhibition by phenacetyl and phenylbenzoyl hydroxamates. J Med Chem 64:2186\u20132204","journal-title":"J Med Chem"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-024-02023-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-024-02023-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-024-02023-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T13:07:57Z","timestamp":1731416877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-024-02023-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":44,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2023"],"URL":"https:\/\/doi.org\/10.1007\/s10495-024-02023-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4661784\/v1","asserted-by":"object"}]},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,12]]},"assertion":[{"value":"18 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}